NCT06195735View on ClinicalTrials.gov

Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL

CompletedOBSERVATIONAL
Enrollment

649

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2023

Conditions
Acute Lymphoblastic Leukemia
Trial Locations (1)

8200

Aarhus University Hospital, Aarhus N

All Listed Sponsors
collaborator

Uppsala University

OTHER

collaborator

University of Aarhus

OTHER

lead

Aarhus University Hospital

OTHER

NCT06195735 - Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL | Biotech Hunter | Biotech Hunter